Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries – PR Newswire
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries PR Newswire Source: Author: | Date: 2025-08-18 07:00:00 Source: Author: | Date: 2025-08-18 07:00:00
Kiora CEO to Reveal Latest Retinal Disease Therapeutic Developments at Major Ophthalmology Conference – Stock Titan
Kiora CEO to Reveal Latest Retinal Disease Therapeutic Developments at Major Ophthalmology Conference Stock Titan Source: Author: | Date: 2025-08-07 07:00:00 Source: Author: | Date: 2025-08-07 07:00:00
Racial and ethnic diversity in ophthalmology: a meta-analysis of industry-sponsored phase 3 clinical trials from a single company – Nature
Racial and ethnic diversity in ophthalmology: a meta-analysis of industry-sponsored phase 3 clinical trials from a single company Nature Source: Author: | Date: 2025-06-12 07:00:00 Source: Author: | Date: 2025-06-12 07:00:00
FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative – Stock Titan
FDA Green Lights Amneal’s $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative Stock Titan Source: Author: | Date: 2025-06-12 07:00:00 Source: Author: | Date: 2025-06-12 07:00:00
Peptide Eye Drops Offer Hope for Dry AMD
Researchers from the Natural Product Drug Development Center at the Korea Institute of Science and Technology (KIST), led by Dr. Moon-Hyeong Seo, have developed an innovative therapeutic agent for dry age-related macular degeneration (AMD) in the form of peptide-based eye…
Galimedix Begins Phase 2 Trial for GAL-101 in Dry AMD
Galimedix Therapeutics has announced the initiation of a phase 2 clinical study called eDREAM (NCT06659549), evaluating the efficacy and safety of GAL-101 eye drops in patients with dry age-related macular degeneration (AMD) and geographic atrophy (GA). About the Phase 2…
Glaukos Submits FDA Application for Epioxa Therapy
Glaukos Corporation has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its innovative corneal cross-linking therapy, Epioxa (Epi-on). This next-generation treatment is designed for patients with keratoconus and represents a significant advancement…
4DMT Reveals Preclinical Data on TVE Platform
4D Molecular Therapeutics (4DMT) has announced the publication of preclinical data underscoring the capabilities of its Therapeutic Vector Evolution (TVE) platform. The research focuses on the intravitreal R100 vector and the R100-based genetic medicine 4D-150. This groundbreaking study, titled “Design…
Opus Gets FDA SPA for APX3330 Phase 3 Trial
Opus Genetics has announced a key regulatory milestone, securing a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for its Phase 3 clinical trial of APX3330. The oral treatment is being evaluated for moderate to…